HDAC1 and plasma cell myeloma: Early targeting of this family of 11 enzymes(HDAC1–11) afforded a first generation of broadly acting inhibitorswith medicinal applications in oncology, specifically in cutaneousand peripheral T-cell lymphomas and in multiple myeloma.